Swedish Orphan Biovitrum AB
SOBI
Kedudukan dalam Saham
#1386
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Harga Saham
$45.96
Modal Pasaran
$15.97B
Perubahan (1 hari)
-0.70%
Perubahan (1 tahun)
36.86%
Negara
SE
Perdagangan Swedish Orphan Biovitrum AB (SOBI)
Kategori
Healthcare
Bilangan saham terbitan bagi Swedish Orphan Biovitrum AB (SOBI)
Bilangan saham terbitan setakat October 2026: 0
Menurut laporan kewangan terkini dan harga saham Swedish Orphan Biovitrum AB, bilangan saham terbitan semasa ialah 0. Pada akhir October 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Swedish Orphan Biovitrum AB (SOBI) dari 2002 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2025 | 344.30M | 0.75% |
| 2024 | 341.73M | 5.91% |
| 2023 | 322.66M | 4.26% |
| 2022 | 309.48M | 0.19% |
| 2021 | 308.90M | 0.13% |
| 2020 | 308.49M | 0.69% |
| 2019 | 306.38M | 13.22% |
| 2018 | 270.60M | 0.59% |
| 2017 | 269.02M | 0.25% |
| 2016 | 268.36M | 0.41% |
| 2015 | 267.28M | 0.79% |
| 2014 | 265.18M | -0.03% |
| 2013 | 265.27M | 0.01% |
| 2012 | 265.23M | 9.54% |
| 2011 | 242.12M | 21.83% |
| 2010 | 198.74M | 252.27% |
| 2009 | 56.42M | -49.59% |
| 2008 | 111.91M | 9.91% |
| 2007 | 101.82M | -1.51% |
| 2006 | 103.39M | 1.53% |
| 2005 | 101.82M | 0.00% |
| 2004 | 101.82M | 0.00% |
| 2003 | 101.82M | 0.00% |
| 2002 | 101.82M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 445.06M | - |
US
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 105.38M | - |
US
|
|
| 18.05B | - |
HK
|
